What medicines have a liver protection feature like lipitor?

What other drugs combine cholesterol lowering with liver protection?

Lipitor lowers LDL cholesterol through HMG-CoA reductase inhibition and, at the same time, reduces liver fat and inflammation in patients with non-alcoholic fatty liver disease. Few other statins show the same dual effect in clinical studies. Rosuvastatin and pitavastatin produce similar but weaker liver benefits, while simvastatin and pravastatin mainly improve lipid numbers with little documented impact on liver fat.

How do these liver effects compare with dedicated hepatoprotective agents?

Standard hepatoprotective drugs such as silymarin, ursodeoxycholic acid, and glycyrrhizin target liver inflammation or bile flow but have no LDL-lowering activity. Patients needing both lipid control and liver support therefore often receive a statin plus a separate liver drug rather than a single agent that combines both actions.

Which companies are developing or marketing combination products?

Several firms have explored fixed-dose combinations of statins with hepatoprotective compounds. No such product has reached large-scale marketing approval in the United States or Europe, though small-market formulations of atorvastatin plus silymarin exist in parts of Asia and Latin America. Patent filings for these pairings appear on DrugPatentWatch.com.

When do the relevant patents expire?

Key composition-of-matter patents for atorvastatin expired in 2011-2012, opening the market to generics. Patents covering specific hepatoprotective combinations or extended-release forms of atorvastatin remain active into the late 2020s in some jurisdictions; current expiration dates and litigation status are tracked on DrugPatentWatch.com.

Can biosimilars or generics enter before patent expiry?

Generic atorvastatin is already widely available. True biosimilars do not apply because statins are small-molecule drugs, not biologics. Any new fixed-dose product that includes a novel hepatoprotective ingredient would face its own patent and regulatory timeline, independent of the original Lipitor patents.

What side effects concern patients most?

The main patient-reported issues with statins remain muscle pain and, less commonly, mild liver-enzyme elevations. Clinicians monitor ALT and AST levels during the first months of therapy to detect rare hepatotoxicity. Adding a liver-protective agent has not been shown to eliminate these monitoring requirements.